|
Orthologous residues
|
|
EB3 (human): S176‑p, EB3 iso2 (human): S161‑p, EB3 (mouse): S176‑p, EB3 iso2 (mouse): S161‑p, EB3 (rat): S176‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
cervical cancer, cervical adenocarcinoma
|
|
Relevant cell lines - cell types - tissues:
HeLa S3 (cervical)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Comments:
in mitotic cells
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
AurA (human)
|
pharmacological inhibitor of upstream enzyme
|
|
|
KINASE
|
AurB (human)
|
pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
nocodazole
|
|
|
|
increase
|
|
|
VX-680
|
nocodazole
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation, protein stabilization, ubiquitination
|
|
Effect of modification (process):
cell cycle regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
SIAH1 (human)
|
|
Disrupts
|
|
|
pull-down assay, in vitro
|
|
